CVS Caremark Study of Newly Diagnosed Diabetes Patients

A new CVS Caremark (NYSE: CVS) study has found that physicians in 35 percent of cases involving more than 250,000 newly diagnosed diabetes patients did not follow the American Diabetes Association/European Association for the Study of Diabetes consensus guidelines for recommended treatment.

Read more

Posted in Other News